ClinicalTrials.gg
RecruitingNCT07620314Updated Jul 20, 2026

Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

A Phase 1 interventional study of KSVCBD injection in Non-Hodgkin's Lymphoma, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Chinese PLA General Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, Non-Hodgkin by Chinese PLA General Hospital — 10 open to participants now, 10 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Chinese PLA General Hospital.

Planned enrollment
10th of 10
9 · median 30
Started
2026
with 2 others
Phase 1
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Lymphoma, Non-Hodgkin by Chinese PLA General Hospital, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, and was the 9th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

10 of the 11 studies in Lymphoma, Non-Hodgkin by Chinese PLA General Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma, Non-Hodgkin by Chinese PLA General Hospital, or all of them as a file.
02

Study summary

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) CD19 and/or BCMA.

Read the detailed description

A structurally modified, third-generation, self-inactivating lentiviral vector was used in KSVCBD injection. This modified vector exhibits reduced immunogenicity and enables efficient T-cell targeting, thereby facilitating the in vivo generation of CD19/BCMA CAR T cells from endogenous T cells. Simultaneously targeting BCMA to eliminate plasma cells producing anti-lentivirus and anti-CD19 scFv antibodies enables repeated infusion. The safety and efficacy of CD19/BCMA dual-target autologous CAR-T therapy for the treatment of r/r B-cell NHL have already been validated in clinical studies. In this study, dose-escalation research will be conducted to explore the safety and preliminary efficacy of CD19/BCMA dual-target in vivo CAR-T therapy in patients with r/r B-cell NHL who are positive for CD19 and/or BCMA expression.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18-75 years (inclusive), any gender.
  2. Subjects must meet the following diagnostic and treatment criteria:

    2.1Histologically or confirmed B-NHL (according to the 2016 WHO classification of lymphoid neoplasms):

    • Diffuse large B-cell lymphoma, not otherwise specified.
    • Primary mediastinal large B-cell lymphoma.
    • Diffuse large B-cell lymphoma transformed from follicular lymphoma (TFL).
    • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    • Follicular lymphoma (FL).
    • High-grade B-cell lymphoma, not otherwise specified.
    • Mantle cell lymphoma (pathologically confirmed, with monoclonal B cells carrying t(11.14) and/or overexpressing cyclin D1).
    • Marginal zone lymphoma (including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue [MALT] lymphoma).

    2.2Subjects must be in a state during the screening period:

    • Definition of relapse: Disease progression (PD) after achieving remission (including PR or CR) following at least one standard treatment regimen (must include rituximab and anthracyclines).
    • Definition of refractory: Must meet any of the following criteria:

    Best response of stable disease (SD) or PD after at least 4 cycles of standard treatment (e.g., 4 cycles of R-CHOP).

    Achieved remission after at least 6 cycles of first-line standard treatment but experienced PD within 6 months.

    Best response of PD after first-line standard treatment. Relapse (must be -proven) or PD within 12 months after stem cell transplantation (ASCT). if salvage therapy was received, no response (SD or PD) to the last line of treatment.

    • For TFL, subjects must have received adequate prior treatment for follicular lymphoma, at least one line of treatment for TFL after transformation, and be relapsed or refractory after the last line of treatment.
    • For mantle cell lymphoma, prior treatment must include anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy (except for CD20-negative cases), and BTK inhibitor therapy.
    • For indolent lymphomas (grade 1-3a FL and marginal zone lymphoma), subjects must have received at least two prior lines of therapy.
    • For other types, prior treatment must include anti-CD20 therapy (except for CD20-negative cases) and anthracycline-containing chemotherapy.

    2.3Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.

  3. Intranodal lesion with long-axis diameter > 1.5 cm, or extranodal lesion with long-axis diameter > 1.0 cm (according to the 2014 Lugano response criteria).
  4. Positive expression of CD19 and/or BCMA in tumor tissue confirmed by flow cytometry and/or histopathology (previous pathology or flow cytometry diagnosis of CD19 and/or BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and/or anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and/or BCMA.
  5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).
  6. (ECOG) performance status ≤ 2.

Key Exclusion Criteria:

  1. Expected survival \< 3 months.
  2. History of or concurrent active . Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.
  3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.
  4. Solitary extramedullary soft tissue plasmacytoma.
  5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.
  6. Presence of or symptoms of CNS metastasis.
  7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.
  8. Presence of uncontrolled active infections.
  9. Positive for (HIV) antibody, positive for Treponema pallidum antibody, positive for surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.
  10. Known active disease requiring systemic treatment.
  11. Known severe allergy to the study drug or any of its components.
  12. Pregnant or breastfeeding women.
  13. Receipt of a within 6 weeks prior to enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    KSVCBD injection

    Administered by IV infusion

    Biological: KSVCBD injection

Interventions

  • BiologicalKsvcbdStudies of KsvcbdKsvcbd pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA. Three dose levels are predefined, and KSVCBD will be dose-escalated per the protocol-specified doses

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity (DLT)

    DLT is defined as any of the following adverse events (AEs) related to KSVCBD infusion occurring within 28 days after KSVCBD infusion

    Time frame: Within 28 days post-infusion

  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    AEs refer to any adverse medical events occurring in subjects from the initiation of KSVCBD administration during clinical trials. SAEs denote events involving death, life-threatening conditions, significant disability/incapacity, hospitalization or prolonged hospitalization arising after KSVCBD administration in subjects

    Time frame: Within 24 months post-infusion

  3. Incidence and severity of adverse events of special interest (AESI)

    AESI including grade ≥ 3 Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and infections

    Time frame: Within 24 months post-infusion

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR includes Complete Remission (CR) and Partial Remission (PR).

    Time frame: Within 24 months post-infusion

  2. Duration of Response (DOR)

    Time from first documented PR or better to relapse or disease progression, or death from any cause

    Time frame: Within 24 months post-infusion

  3. Time to Response (TTR)

    Time from administration to first documented PR or better.

    Time frame: Within 24 months post-infusion

  4. Progression-Free Survival (PFS)

    Time from administration to disease progression or death from any cause, whichever occurs first.

    Time frame: Within 24 months post-infusion

  5. Overall Survival (OS)

    Time from administration to death from any cause.

    Time frame: Within 24 months post-infusion

  6. KSVCBD lentiviral particle concentration

    KSVCBD lentiviral particle concentration in peripheral blood.

    Time frame: Within 24 months post-infusion

  7. Number of CAR-positive T cells

    Number of CAR-positive T cells in peripheral blood.

    Time frame: Within 24 months post-infusion

  8. CAR gene copy number

    CAR gene copy number in peripheral blood.

    Time frame: Within 24 months post-infusion

  9. Number of CD19-positive cells

    Number of CD19-positive cells in peripheral blood.

    Time frame: Within 24 months post-infusion

  10. Number of BCMA-positive cells

    Number of BCMA-positive cells in peripheral blood.

    Time frame: Within 24 months post-infusion

07

Study locations

1 of 1 sites recruiting
  • Biotherapeutic Department of Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
    Recruiting
    • Weidong Han, M.D. · Contacthanwdrsw@sina.com · +86-10-66937463
    • Yang Liu, M.D. · Sub investigator
    • Jinhong Shi, M.S. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 123 non-industry phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's planned 29 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Mar 30, 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620314
Responsible party
Han weidong (Director of Biotherapeutic Department, Chinese PLA General Hospital) — Principal investigator
First posted
Jun 2, 2026
Start date
Jul 16, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Weidong Han, M.D.
Contact
hanwdrsw@sina.com
+86-010-55499341

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ksvcbd

Start the discussion